Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Accumulated Expenses: 2019-2024

Historic Other Accumulated Expenses for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $33.1 million.

  • BridgeBio Pharma's Other Accumulated Expenses rose 615.83% to $92.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year increase of 615.83%. This contributed to the annual value of $33.1 million for FY2024, which is 610.14% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Other Accumulated Expenses is $33.1 million, which was up 610.14% from $4.7 million recorded in FY2023.
  • BridgeBio Pharma's Other Accumulated Expenses' 5-year high stood at $33.1 million during FY2024, with a 5-year trough of $4.7 million in FY2023.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $5.2 million (2022), whereas its average is $14.3 million.
  • In the last 5 years, BridgeBio Pharma's Other Accumulated Expenses plummeted by 82.86% in 2022 and then soared by 610.14% in 2024.
  • BridgeBio Pharma's Other Accumulated Expenses (Yearly) stood at $13.3 million in 2020, then spiked by 126.85% to $30.3 million in 2021, then tumbled by 82.86% to $5.2 million in 2022, then declined by 10.27% to $4.7 million in 2023, then skyrocketed by 610.14% to $33.1 million in 2024.